PE20240114A1 - Inhibidor de integrina y usos de este - Google Patents
Inhibidor de integrina y usos de esteInfo
- Publication number
- PE20240114A1 PE20240114A1 PE2023001662A PE2023001662A PE20240114A1 PE 20240114 A1 PE20240114 A1 PE 20240114A1 PE 2023001662 A PE2023001662 A PE 2023001662A PE 2023001662 A PE2023001662 A PE 2023001662A PE 20240114 A1 PE20240114 A1 PE 20240114A1
- Authority
- PE
- Peru
- Prior art keywords
- salts
- determined
- crystalline forms
- peaks
- forms
- Prior art date
Links
- 229940125798 integrin inhibitor Drugs 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000002411 thermogravimetry Methods 0.000 abstract 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Refiere a formas cristalinas de sales de inhibidores de integrina, las cuales son sales del acido (S)-4-((2-metoxietil)(4-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)butil)amino)-2-(quinazolin-4-ilamino)butanoico, sales de fosfato o fumarato. Dichas formas se caracterizan por presentar un patron de difraccion de polvo de rayos X (XRPD) con picos en angulos 2-theta de 4.31-6.76 grados; picos endotermicos de 88.3 °C - 197.6 °C determinados por calorimetria diferencial de barrido (DSC); y una perdida de peso de aproximadamente 13.02 % despues de calentarse a 26.0°C - 125.0°C determinada por un analisis termogravimetrico (TGA). Asimismo, se mencionan metodos para la preparacion de las formas cristalinas; y composiciones farmaceuticas a base de dichas formas y un portador o excipiente farmaceuticamente aceptables, para el tratamiento de enfermedades fibroticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063116042P | 2020-11-19 | 2020-11-19 | |
PCT/US2021/072510 WO2022109598A1 (en) | 2020-11-19 | 2021-11-19 | Integrin inhibitor and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240114A1 true PE20240114A1 (es) | 2024-01-22 |
Family
ID=81709878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001662A PE20240114A1 (es) | 2020-11-19 | 2021-11-19 | Inhibidor de integrina y usos de este |
Country Status (18)
Country | Link |
---|---|
US (1) | US12018025B2 (es) |
EP (1) | EP4247472A1 (es) |
JP (1) | JP2023550428A (es) |
KR (1) | KR20230121761A (es) |
CN (1) | CN116710169A (es) |
AU (1) | AU2021381516A1 (es) |
CA (1) | CA3173755A1 (es) |
CL (1) | CL2023001418A1 (es) |
CO (1) | CO2023006522A2 (es) |
CR (1) | CR20230262A (es) |
CU (1) | CU20230026A7 (es) |
DO (1) | DOP2023000101A (es) |
EC (1) | ECSP23045278A (es) |
IL (1) | IL302651A (es) |
MX (1) | MX2023005889A (es) |
PE (1) | PE20240114A1 (es) |
TW (1) | TW202235417A (es) |
WO (1) | WO2022109598A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
IL279717B2 (en) | 2018-06-27 | 2024-05-01 | Pliant Therapeutics Inc | Amino acid compounds with non-branched linkers and methods of use |
TW202408530A (zh) * | 2022-07-09 | 2024-03-01 | 美商普萊恩醫療公司 | 整合素抑制劑及其與其他藥劑併用之用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
JP2018515424A (ja) | 2015-03-10 | 2018-06-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗アルファvベータ1インテグリン阻害剤及び使用方法 |
EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING |
EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
RU2769702C2 (ru) | 2017-02-28 | 2022-04-05 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
BR112020018064A2 (pt) | 2018-03-07 | 2020-12-22 | Pliant Therapeutics, Inc. | Compostos de aminoácidos e métodos de uso |
IL279717B2 (en) | 2018-06-27 | 2024-05-01 | Pliant Therapeutics Inc | Amino acid compounds with non-branched linkers and methods of use |
JP7314135B2 (ja) * | 2018-07-20 | 2023-07-25 | 株式会社半導体エネルギー研究所 | 撮像装置 |
EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INTEGRIN (ALPHA-V)(BETA-6) INHIBITORS |
EP3843728A4 (en) | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
JP2022523621A (ja) * | 2018-12-28 | 2022-04-26 | ルナピービーシー | コミュニティデータの集約、完成、修正、および使用 |
US11730144B2 (en) * | 2019-02-15 | 2023-08-22 | Clean Bite, Llc | Oral hygiene appliance |
SG11202110889WA (en) * | 2019-04-08 | 2021-10-28 | Pliant Therapeutics Inc | Dosage forms and regimens for amino acid compounds |
MX2022005904A (es) | 2019-11-15 | 2022-09-07 | Pliant Therapeutics Inc | Composiciones y metodos para la activacion de integrinas. |
MX2022013753A (es) * | 2020-05-07 | 2023-01-30 | Pliant Therapeutics Inc | Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. |
IL298082A (en) * | 2020-06-03 | 2023-01-01 | Gilead Sciences Inc | lpa receptor antagonists and uses thereof |
TW202233224A (zh) * | 2020-10-21 | 2022-09-01 | 美商寇峇有限公司 | 用組合療法治療纖維化之方法 |
TW202308637A (zh) | 2021-04-30 | 2023-03-01 | 美商普萊恩醫療公司 | 整合素抑制劑之擴大劑量方案 |
CA3173754A1 (en) | 2021-09-03 | 2024-03-02 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
IL312083A (en) | 2021-10-14 | 2024-06-01 | Pliant Therapeutics Inc | Integrin inhibitors and their uses in combination with other substances |
WO2023225119A1 (en) | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
-
2021
- 2021-11-19 AU AU2021381516A patent/AU2021381516A1/en active Pending
- 2021-11-19 WO PCT/US2021/072510 patent/WO2022109598A1/en active Application Filing
- 2021-11-19 PE PE2023001662A patent/PE20240114A1/es unknown
- 2021-11-19 JP JP2023530225A patent/JP2023550428A/ja active Pending
- 2021-11-19 CU CU2023000026A patent/CU20230026A7/es unknown
- 2021-11-19 CN CN202180090550.5A patent/CN116710169A/zh active Pending
- 2021-11-19 EP EP21895890.8A patent/EP4247472A1/en active Pending
- 2021-11-19 US US17/531,074 patent/US12018025B2/en active Active
- 2021-11-19 CA CA3173755A patent/CA3173755A1/en active Pending
- 2021-11-19 TW TW110143265A patent/TW202235417A/zh unknown
- 2021-11-19 CR CR20230262A patent/CR20230262A/es unknown
- 2021-11-19 MX MX2023005889A patent/MX2023005889A/es unknown
- 2021-11-19 KR KR1020237020570A patent/KR20230121761A/ko unknown
- 2021-11-19 IL IL302651A patent/IL302651A/en unknown
-
2023
- 2023-05-17 CL CL2023001418A patent/CL2023001418A1/es unknown
- 2023-05-17 CO CONC2023/0006522A patent/CO2023006522A2/es unknown
- 2023-05-18 DO DO2023000101A patent/DOP2023000101A/es unknown
- 2023-06-16 EC ECSENADI202345278A patent/ECSP23045278A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2023005889A (es) | 2023-06-06 |
EP4247472A1 (en) | 2023-09-27 |
IL302651A (en) | 2023-07-01 |
AU2021381516A1 (en) | 2023-06-22 |
WO2022109598A1 (en) | 2022-05-27 |
CA3173755A1 (en) | 2022-05-27 |
CO2023006522A2 (es) | 2023-06-09 |
JP2023550428A (ja) | 2023-12-01 |
CU20230026A7 (es) | 2024-01-10 |
TW202235417A (zh) | 2022-09-16 |
US12018025B2 (en) | 2024-06-25 |
CN116710169A (zh) | 2023-09-05 |
ECSP23045278A (es) | 2023-07-31 |
KR20230121761A (ko) | 2023-08-21 |
DOP2023000101A (es) | 2023-09-29 |
US20220177468A1 (en) | 2022-06-09 |
CL2023001418A1 (es) | 2023-10-30 |
CR20230262A (es) | 2023-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20240114A1 (es) | Inhibidor de integrina y usos de este | |
KR101794020B1 (ko) | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 | |
AR076433A1 (es) | Sales inhibidoras de cdk | |
HRP20161696T4 (hr) | Tenofovir alafenamid hemifumarat | |
CL2020002562A1 (es) | (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
NZ737725A (en) | Crystalline forms of a bruton’s tyrosine kinase inhibitor | |
HRP20210144T1 (hr) | Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primjena u liječenju raka | |
TN2018000219A1 (en) | Soluble guanylate cyclase stimulators | |
CY1117431T1 (el) | 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου | |
MD3601283T2 (ro) | Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată | |
WO2016105564A1 (en) | Quinazoline derivatives used to treat hiv | |
AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
EA201492125A1 (ru) | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 | |
ES2680146T3 (es) | Hidrocloruro de rilpivirina | |
PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
NI201300103A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [ 2, 3-d] PIRIMIDINA TROPOMIOSINA | |
HRP20211779T1 (hr) | Postupak priprave derivata kinolin-2-il-fenilamina i njihovih soli | |
RU2013145518A (ru) | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение | |
CA2888002A1 (en) | Solid forms of nilotinib hydrochloride | |
DK2804863T3 (en) | NEW FORMS AND SALTS OF A dihydropyrrolo- [1,2-C] IMIDAZOLYLALDOSTERONSYNTASE OR aromatase | |
BRPI0111140B1 (pt) | Forma polimórfica, uso da mesma, e, composição farmacêutica | |
AR077422A1 (es) | Sales de inhibidores de plk | |
EP1682182A1 (de) | Neue kombination enthaltend einen stimulator der löslichen guanylatcyclase und einen lipidsenker | |
EP0536853B1 (en) | Process for the preparation of N1,N4-diethylspermine |